Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Spectral Med Inc

Healthcare CA EDT

1.32CAD
0.02(1.54%)

Last update at 2026-03-10T20:00:00Z

Day Range

1.301.34
LowHigh

52 Week Range

0.551.76
LowHigh

Fundamentals

  • Previous Close 1.30
  • Market Cap428.82M
  • Volume28388
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.19500M
  • Revenue TTM2.71M
  • Revenue Per Share TTM0.009
  • Gross Profit TTM 1.69M
  • Diluted EPS TTM-0.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -15.39500M -15.50700M -9.59300M -8.78500M -9.09800M
Minority interest - - - - -
Net income -15.40200M -15.66200M -11.29900M -8.94100M -9.07500M
Selling general administrative 11.62M 4.83M 8.01M 9.43M 10.11M
Selling and marketing expenses - 6.47M - - -
Gross profit 1.02M 0.66M 0.98M 1.22M 1.47M
Reconciled depreciation 0.25M 0.22M 0.27M 0.29M 0.30M
Ebit -12.21800M -14.17300M -9.44000M -8.60100M -9.08900M
Ebitda -11.96700M -13.95500M -9.16800M -8.30700M -8.78500M
Depreciation and amortization 0.25M 0.22M 0.27M 0.29M 0.30M
Non operating income net other - - - - -
Operating income -11.99700M -11.42100M -9.44000M -8.60100M -9.08900M
Other operating expenses 14.28M 13.02M 8.92M 10.56M 11.04M
Interest expense 3.18M 1.33M 0.10M 0.03M 0.03M
Tax provision - - - - -
Interest income - - - - -
Net interest income -3.17700M -1.33400M -0.10400M -0.02800M -0.03200M
Extraordinary items -0.00700M -0.15500M -3.65300M - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.15M 1.71M 0.16M -0.02300M
Total revenue 2.29M 1.60M 1.67M 2.05M 2.10M
Total operating expenses 13.02M 12.08M 8.23M 9.73M 10.41M
Cost of revenue 1.27M 0.94M 0.68M 0.83M 0.63M
Total other income expense net -3.39800M -4.08600M -0.15300M -0.18400M -0.00900M
Discontinued operations - - -3.65300M -3.65300M -3.65300M
Net income from continuing ops -15.39500M -15.50700M -9.59300M -8.78500M -9.09800M
Net income applicable to common shares -15.40200M -15.66200M -11.25000M -8.78500M -9.09800M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 5.32M 5.21M 12.00M 11.55M 8.16M
Intangible assets 0.17M 0.19M 0.21M 0.23M 0.25M
Earning assets - - - - -
Other current assets - 0.62M 0.28M 0.97M 0.39M
Total liab 32.87M 21.76M 14.52M 7.47M 8.83M
Total stockholder equity -27.54500M -16.54900M -2.52300M 4.08M -0.66900M
Deferred long term liab - - - - -
Other current liab 9.74M 7.53M 1.52M 1.08M 0.98M
Common stock - 87.06M 87.05M 84.36M 71.87M
Capital stock 90.57M 87.06M 87.05M 84.36M 71.87M
Retained earnings -140.83900M -125.43700M -109.74400M -98.49400M -89.70900M
Other liab - - 4.01M 4.68M 5.35M
Good will - - - - -
Other assets - - - - -
Cash 2.99M 2.95M 8.41M 8.89M 5.81M
Cash and equivalents - - - - -
Total current liabilities 27.45M 10.24M 3.96M 2.30M 2.90M
Current deferred revenue - 0.73M 0.70M 0.69M 0.68M
Net debt 11.44M 5.61M -1.76900M -8.30800M -5.14000M
Short term debt - 0.39M 0.10M 0.09M 0.09M
Short long term debt 14.43M 0.26M - - -
Short long term debt total - 8.56M 6.64M 0.58M 0.67M
Other stockholder equity - 8.92M 20.17M 18.22M 17.17M
Property plant equipment - - 0.70M 1.06M 1.11M
Total current assets 4.46M 4.12M 10.09M 10.26M 6.80M
Long term investments 0.00000M 0.00000M 1.00M - -
Net tangible assets - - -2.73400M 3.85M -0.91500M
Short term investments - 0.61M - - -
Net receivables 0.30M 0.19M 1.06M 0.20M 0.26M
Long term debt - 7.68M 6.13M - -
Inventory 0.23M 0.37M 0.34M 0.29M 0.35M
Accounts payable 0.99M 1.60M 1.65M 0.44M 1.16M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 12.91M - - -2.93300M
Additional paid in capital - - - - -
Common stock total equity - - - - 71.87M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.86M 1.09M 1.91M 1.29M 1.36M
Capital lease obligations 0.50M 0.62M 0.52M 0.58M 0.67M
Long term debt total - - 6.55M 0.49M 0.58M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.02700M -0.18500M -0.03300M -0.32500M -0.29700M
Change to liabilities - - 0.96M -1.27500M 7.16M
Total cashflows from investing activities -0.02700M -0.18500M -0.03300M -0.32500M -0.29700M
Net borrowings 9.74M 3.93M 6.71M -0.11300M -0.10900M
Total cash from financing activities 8.88M 5.44M 9.48M 12.16M 5.18M
Change to operating activities - - 0.60M -0.48600M -0.23400M
Net income -15.39500M -15.66200M -11.25000M -8.78500M -9.09800M
Change in cash 0.04M -5.46200M -0.47600M 3.08M 4.37M
Begin period cash flow 2.95M 8.41M 8.89M 5.81M 1.44M
End period cash flow 2.99M 2.95M 8.41M 8.89M 5.81M
Total cash from operating activities -8.81800M -10.72100M -9.92800M -8.70100M -0.32400M
Issuance of capital stock - 0.00000M 4.03M 10.00M 5.10M
Depreciation 0.25M 0.22M 0.27M 0.29M 0.30M
Other cashflows from investing activities - - 0.00000M 0.16M 0.02M
Dividends paid 0.00000M 0.00000M - - -
Change to inventory 0.14M -0.02600M -0.04700M -0.05100M -0.07200M
Change to account receivables -0.26500M 0.87M -0.85100M 0.06M 0.01M
Sale purchase of stock 1.15M - 4.11M 13.41M 6.08M
Other cashflows from financing activities -2.01500M 1.51M 5.55M 2.28M 0.19M
Change to netincome - - 0.39M 1.55M 1.08M
Capital expenditures 0.03M 0.18M 0.03M 0.48M 0.32M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.01M -0.40600M 0.66M -1.75700M 7.39M
Stock based compensation 1.68M 1.49M 1.20M 1.26M 0.88M
Other non cash items 3.64M 3.64M -0.80600M 0.29M 0.20M
Free cash flow -8.84500M -10.90600M -9.96100M -9.18400M -0.63900M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EDT
Spectral Med Inc		 0.02 1.54% 1.32 - - 138.96 49.87 149.87 -7.5083

Reports Covered

Stock Research & News

View All

Profile

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Spectral Med Inc

135 The West Mall, Toronto, ON, Canada, M9C 1C2

Key Executives

Name Title Year Born
Mr. Christopher Seto CEO & Director NA
Dr. John A. Kellum M.D. Chief Medical Officer NA
Ms. Debra-Anne M. Foster B.Sc., RN, CCRC VP of Clinical Devel. NA
Mr. Blair McInnis Chief Financial Officer NA
Mr. Sam Amory Pres of Dialco Medical Inc. NA
Mr. Christopher Seto CEO, CFO & Director NA
Mr. Christopher Seto CEO, Interim CFO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.